<?xml version="1.0" encoding="UTF-8"?>
<p>Targeting the oncogenic protein kinases has emerged as a promising strategy in the development of new anticancer agents in the last three decades
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2</sup>
 </xref>. Currently, more than 40 kinase inhibitors were approved by the FDA for the treatment of different types of cancers
 <xref rid="CIT0003" ref-type="bibr">
  <sup>3â€“5</sup>
 </xref>. Among these inhibitors, the cyclin-dependent kinase inhibitors (CDKIs) attracted much attention which could be due to the important role of CDKs in cell division and differentiation
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0007" ref-type="bibr">
  <sup>7</sup>
 </xref>. Among the CDK family, CDK-2 plays an important role in the progression of cells from G
 <sub>1</sub> to S cell cycle phases
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0007" ref-type="bibr">
  <sup>7</sup>
 </xref>. The overexpression of CDK-2 was also reported in several solid tumours such as breast
 <xref rid="CIT0008" ref-type="bibr">
  <sup>8</sup>
 </xref>, colon
 <xref rid="CIT0009" ref-type="bibr">
  <sup>9</sup>
 </xref>, and ovarian cancers
 <xref rid="CIT0010" ref-type="bibr">
  <sup>10</sup>
 </xref>. In addition, the increase in CDK-2 expression was also associated with the induction of the radio-resistance in glioblastoma cells
 <xref rid="CIT0011" ref-type="bibr">
  <sup>11</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0012" ref-type="bibr">
  <sup>12</sup>
 </xref>, and metastasis in prostate cancer
 <xref rid="CIT0013" ref-type="bibr">
  <sup>13</sup>
 </xref>. CDK-2 also has a crucial role in DNA replication and apoptosis in different types of cancer
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0012" ref-type="bibr">
  <sup>12</sup>
 </xref>.
</p>
